Literature DB >> 17499399

A critical contribution of both CD28 and ICOS in the adjuvant activity of Neisseria meningitidis H44/76 LPS and lpxL1 LPS.

Miranda E A T van Berkel1, Elise H R Schrijver, Andries van Mourik, Kiki Tesselaar, Peter van der Ley, Liana Steeghs, Mariëtte A Oosterwegel.   

Abstract

The development of novel vaccines against Neisseria meningitidis recently gained momentum by the generation of penta-acylated lpxL1 LPS which has similar adjuvant activity, but reduced endotoxic activity as compared to hexa-acylated wild type (H44/76) LPS. We investigated the costimulation requirements for the adjuvant activity of both forms of LPS by immunizing CD28-, ICOS- and B7.1/2/ICOS-deficient mice. Both ICOS and CD28 appeared essential for optimal adjuvant activity of H44/76 LPS or lpxL1 LPS. Interestingly, ICOS-mediated costimulation predominates in the adjuvant activity of lpxL1 LPS, while both ICOS and CD28 are required for H44/76 LPS adjuvant activity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17499399     DOI: 10.1016/j.vaccine.2007.04.016

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  2 in total

1.  Regulation of T cell response by blocking the ICOS signal with the B7RP-1-specific small antibody fragment isolated from human antibody phage library.

Authors:  Masatoshi Maeda; Yuji Ito; Takaaki Hatanaka; Shuhei Hashiguchi; Masaharu Torikai; Toshihiro Nakashima; Kazuhisa Sugimura
Journal:  MAbs       Date:  2009-09-26       Impact factor: 5.857

2.  CD28 homodimer interface mimetic peptide acts as a preventive and therapeutic agent in models of severe bacterial sepsis and gram-negative bacterial peritonitis.

Authors:  Girish Ramachandran; Raymond Kaempfer; Chun-Shiang Chung; Anat Shirvan; Abdullah B Chahin; John E Palardy; Nicolas A Parejo; Yaping Chen; Melissa Whitford; Gila Arad; Dalia Hillman; Ronen Shemesh; William Blackwelder; Alfred Ayala; Alan S Cross; Steven M Opal
Journal:  J Infect Dis       Date:  2014-10-09       Impact factor: 5.226

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.